Hepatitis C virus infection in haemodialysis and kidney transplant patients.

Détails

ID Serval
serval:BIB_7FCE9FF058CD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Hepatitis C virus infection in haemodialysis and kidney transplant patients.
Périodique
Reviews in Medical Virology
Auteur(s)
Baid-Agrawal S., Pascual M., Moradpour D., Frei U., Tolkoff-Rubin N.
ISSN
1052-9276
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
18
Numéro
2
Pages
97-115
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Chronic infection with hepatitis C virus (HCV) is an important global health problem. The prevalence of HCV is significantly higher in haemodialysis and kidney transplant patients, as compared to the general population. In spite of the relatively milder liver disease activity reported in HCV-infected haemodialysis patients, HCV infection adversely affects survival. Likewise, HCV has a detrimental effect on both patient and graft survival after kidney transplantation. However, patient survival is significantly better with kidney transplantation compared to remaining on dialysis; therefore, HCV infection alone should not be a contraindication to transplantation. Combination antiviral therapy with pegylated interferon-alpha and low-dose ribavirin is currently evolving in haemodialysis patients. Interferon-alpha (standard/pegylated) is relatively contraindicated after kidney transplantation because of an increased risk of allograft rejection. Therefore, antiviral treatment of transplant candidates while on dialysis remains the best option and may avoid the risk of HCV-associated liver and renal disease after transplantation. Large multi-centre clinical trials are required in HCV-infected haemodialysis and kidney transplant patients in order to define optimal therapeutic strategies before and after transplantation.
Mots-clé
Antiviral Agents/therapeutic use, Clinical Trials as Topic, Disease Progression, Drug Therapy, Combination, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Hepatitis C, Chronic/epidemiology, Humans, Interferon-alpha/therapeutic use, Kidney Transplantation/adverse effects, Kidney Transplantation/mortality, Polyethylene Glycols/therapeutic use, Renal Dialysis/adverse effects, Renal Dialysis/mortality, Ribavirin/therapeutic use, Survival Analysis, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/02/2008 17:07
Dernière modification de la notice
20/08/2019 14:40
Données d'usage